Investors watch RNA therapy companies for signs of future profits

Only a few weeks ago, there was talk of a biotech stock slump, but now some of those same companies are in vogue again, at least in the popular press. Those that make RNA-based therapies are beginning to win over skeptics who are impatiently waiting for commercialization; doubts will remain until they produce a profitable product. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.